WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

Leerink Partners analyst Marc Goodman has maintained their bullish stance on OPT stock, giving a Buy rating yesterday.Invest with Confidence: ...

Opthea Limited (NASDAQ:OPT – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $5.49, but opened at $5.68. Opthea shares last traded at $5.65, with a ...

ONS-5010 (bevacizumab-vikg) was found to be noninferior to ranibizumab for neovascular age-related macular degeneration at week 12.

In addition, DN and DR diseases development are involved in several critical regulators including the cell adhesion molecules (CAMs), the vascular endothelial growth factor (VEGF) family and the Notch ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held ... Bayer has filed its mineralocorticoid receptor antagonist finerenone as a treatment heart failure ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...